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DNA vaccinea b s t r a c t
Highly pathogenic avian inﬂuenza viruses (HPAIVs) cause huge economic losses in the poultry industry
because of high mortality rate in infected ﬂocks and trade restrictions. Protective antibodies, directed
mainly against hemagglutinin (HA), are the primary means of protection against inﬂuenza outbreaks.
A recombinant DNA vaccine based on the sequence of H5 HA from the H5N1/A/swan/Poland/305-
135V08/2006 strain of HPAIV was prepared. Sequence manipulation included deletion of the proteolytic
cleavage site to improve protein stability, codon usage optimization to improve translation and stability
of RNA in host cells, and cloning into a commercially available vector to enable expression in animal cells.
Naked plasmid DNA was complexed with a liposomal carrier and the immunization followed the prime–
boost strategy. The immunogenic potential of the DNA vaccine was ﬁrst proved in broilers in near-to-ﬁeld
conditions resembling a commercial farm. Next, the protective activity of the vaccine was conﬁrmed in
SPF layer-type chickens. Experimental infections (challenge experiments) indicated that 100% of vacci-
nated chickens were protected against H5N1 of the same clade and that 70% of them were protected
against H5N1 inﬂuenza virus of a different clade. Moreover, the DNA vaccine signiﬁcantly limited (or
even eliminated) transmission of the virus to contact control chickens. Two intramuscular doses of
DNA vaccine encoding H5 HA induced a strong protective response in immunized chicken. The effective
protection lasted for a minimum 8 weeks after the second dose of the vaccine and was not limited to the
homologous H5N1 virus. In addition, the vaccine reduced shedding of the virus.
 2014 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/3.0/).Introduction
DNA vaccines are new-generation vaccines offering many
advantages over conventional ones [13]. They are relatively simple,
easy and fast to produce, generate low costs in storage and trans-
port, and are more stable than protein formulations. Numerous
data show the effectiveness of experimental DNA immunizations
against various viral, bacterial, parasitic and cancer diseases.
However, only a few veterinary products have been registered to
date in the USA and Canada, and despite several clinical trials, no
human DNA vaccine is available [6,10]. Various experimental
DNA vaccines have been tested in poultry [15]. The high potential
of DNA immunization, particularly in cases requiring a rapidresponse to an inﬂuenza pandemic have led to the development
of this technology and increase of report on DNA vaccines for
chickens against inﬂuenza [4,8,9,11,12,17,19,23].
The inﬂuenza virion has several structural and non-structural
antigens, namely hemagglutinin (HA), neuraminidase (NA), capsid
protein (M1), ion channel protein (M2), nucleoprotein (NP) and the
components of the viral polymerase PA, PB1 and PB2 [22].
Although detectable antibody responses are observed against
many viral proteins, the major determinants for a protective re-
sponse are antibodies produced against surface glycoprotein HA,
the most prominent antigen of the virus (see the review [20] and
references therein). HA is synthesized as a precursor polypeptide
H0 and is then cleaved into subunits H1 and H2. The HA cleavage
site is the main determinant of the pathogenicity of inﬂuenza
viruses. In low-pathogenic avian inﬂuenza viruses (LPAIVs) the
cleavage site can be limited to a single arginine residue recognized
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viruses (HPAIV) the H0 precursor contains a sequence that can
be recognized by proteases present in nearly all cell types, which
facilitates systemic spread of the virus [20,22].
In the EU, permission to vaccinate poultry against H5N1 HPAI
can be granted after the fulﬁllment of strict requirements laid
down in the EU Directive for the Control of AI (Council Directive
2005/94/EC). The directive is concerned with the high risk of a
‘‘silent spread’’ of the virus due to incomplete protection at a ﬂock
level, leading to the impossibility of differentiating the infected
from the vaccinated individuals in case of usage of inactivated
vaccines. Therefore, considering the needs of the DIVA (Differenti-
ating Infected from Vaccinated Animals) strategy, there is a great
demand for new-generation vaccines [2,5,18]. It is strongly recom-
mended by the OIE and the EU that preventive and emergency vac-
cination should be an additional method of controlling and ﬁghting
the virus in case of disease outbreak, by protecting valuable ﬂocks
and reducing the spread of virus in restriction and buffer zones.
The H5N1 strain of HPAIV which is the object of our studies and
caused the Asian epidemic in 2003 was ﬁrst identiﬁed in domestic
gees in China in 1996 [27]. After several years of spreading and ge-
netic diverging in South Eastern Asia, some strains have crossed
the Russian border and reached the Middle East and Europe [3].
Several local outbreaks appeared in almost all European countries,
both on poultry farms and among wild birds. In March 2006, the
ﬁrst disease outbreak was reported in Poland in mute swans
[14,25]. Despite the high standards of food and animal trade in
the EU due to the intense human and animal movement the risk
of virus re-emergence is high. In this study the immunization
experiments were conducted with common broiler type chicken
grown in a biologically secure poultry-house. The duration of the
immunization experiments was 6 weeks, because such is the
length of broilers’ life. Two intramuscular doses of DNA vaccine
were sufﬁcient to stimulate the anti-HA response in sera of immu-
nized chickens. The second series of experiments involved chal-
lenge with HPAI H5N1 viruses and were conducted in a P3
laboratory using SPF chickens of laying type, which allowed the
time of the experiments to be extended to 8–13 weeks in order
to test for the long-term protection. The challenge experiments
indicated a high protective potential of the tested DNA vaccine.
The immunized SPF chickens were protected in 100% against
H5N1 virus from a homologous clade (clade 2.2) and in 80% against
the H5N1 virus from a heterologous clade (clade 1).Materials and methods
Plasmids and vaccine design
Based on the predicted amino acid sequence of HA from H5N1
A/swan/Poland/305-135V08/2006 strain of HPAIV (EpiFluDatabase
[http://platform.gisaid.org]; Accession No. EPI156789), a synthetic
gene optimized to the domestic chicken codon bias and containing
deletion of the proteolytic cleavage site (from Arg-341 to Arg-346)
was designed (GenBank Accession No. KC172926). Two variants of
the DNA vaccine were prepared: (i) long, codon-optimized HA (aa
1–568) with the original N-terminal signal peptide of 16 amino
acids (aa 1–16) and a deletion of the proteolytic cleavage site
RRRKKR (D341–346) and (ii) short, codon-optimized HA, contain-
ing only aa 17–340 (only H1 subunit, without signal peptide).
The non-optimal codons in the native HA gene sequence were
replaced by codons optimized to chicken codon usage and the
sequence was also checked for the absence of cryptic splice sites
(commercial service by GenScript USA Inc.). The inserts were
cloned into the pCI (Promega) between immediate-early enhan-
cer/promoter from Cytomegalovirus (CMV) and a terminator/polyadenylation signal from SV40. Plasmid DNA was puriﬁed using
NoEndo JETSTAR Plasmid Kit (Genomed, Germany) and suspended
in PBS pH 7.4, and the appropriate amount of DNA (62–250 lg)
was mixed with the Lipofectin transfection reagent (Life Technolo-
gies, USA) as recommended by the manufacturer. In each trial the
same ratio of DNA amount (w):Lipofectin (v), 6:1 was used. The
volume of one dose of vaccine was 160 ll.
Inﬂuenza viruses and stock preparation
Table 1 lists the used inﬂuenza viruses. The HPAIVs were
propagated in the allantoic cavities of embryonated chicken eggs
(Valo-Biomedia, Germany) in biosafety level 3 conditions of the
National Veterinary Research Institute (Pulawy, Poland) and stored
in aliquots at 70 C (for challenge purpose) or inactivated with
0.1% formaldehyde (Sigma–Aldrich, MO, USA) for 2 h at 37 C (for
hemagglutination inhibition test). The LPAIVs were either pur-
chased or kindly provided by others. The viral stocks stored at
70 C were titrated before use.
Immunization and challenge experiments
Broilers (Ross 308) were housed in poultry-house in cages, in
standard commercial conditions including temperature, photope-
riod, litter and fodder. Five independent immunizations of broilers
were conducted. Depending on the experiment, animals (7–15 per
group) were immunized subcutaneously in the neck or intramus-
cularly in the breast muscle with the indicated amount of DNA
complexed with Lipofectin. Blood was collected from the wing
veins, allowed to coagulate, and centrifuged. The collected sera
were kept at 20 C.
Speciﬁc pathogen free (SPF) White Leghorn chickens, housed in
a biosafety level 3 containment of the National Veterinary Research
Institute, Pulawy, were immunized intramuscularly twice (using 1-
ml syringe with 0.5  1.6 mm needle) with the DNA vaccine con-
taining 125 lg of plasmid DNA complexed with Lipofectin. Prior
to the challenge, the chickens were placed in separate isolators
(Montair Andersen B.V., Holland) equipped with HEPA ﬁlters.
Three challenge experiments were performed. The immunized
chickens (10 birds/group in Experiments 1 and 3, and 5 birds in
Experiment 2) as well as control (untreated, fully susceptible
chickens, 2–5/group) were inoculated oculonasally with 106 50%
egg infectious dose (EID50) of the respective virus in the volume
of 100 ll (50 ll into the nares and 50 ll into the eye per bird).
Approximately 24 h after inoculation, 6-week-old contact SPF
chickens (1 or 2 per group) were placed in the same isolators as
the vaccinated chickens to monitor virus transmission. Other de-
tails are shown in Table 2.
Ethic statements
The experiments were approved by the Second Local Ethical
Committee for Animal Experiments at the Medical University of
Warsaw, Permit Number 17/2009 (broilers) or the Second Local
Ethical Committee for Animal Experiments at the University of Life
Sciences in Lublin, Permit No. 26/2012 (SPF chickens). All efforts
were made to minimize suffering. The chickens were monitored
twice a day (morning and afternoon), including weekends. The
immunized chickens were sacriﬁced (humanely euthanized by
decapitation) about 3 weeks after the ﬁnal immunization (about
6 weeks after hatching).
ELISA
The 96-well polystyrene plates (Nunc, Denmark) were coated
overnight at 4 C with 300 ng of HA antigen (A/swan/Poland/
Table 1
Inﬂuenza viruses used in this study.
Experiment Antigen Clade Source
DNA vaccine H5N1 A/swan/Poland/305-
135V08/2006
Clade 2.2 Department of Poultry Diseases, National Veterinary Research Institute, Pulawy,
Poland




– GD Deventer, Netherlands
Challenge Experiments 1 and2 H5N1 A/turkey/Poland/35/07 Clade 2.2 Department of Poultry Diseases, National Veterinary Research Institute, Pulawy,
Poland
Challenge Experiment 3 H5N1 A/crested eagle/Belgium/
01/2004
Clade 1 Dr. T. van den Berg (CODA-CERVA, Brussels, Belgium)







Animal Health and Veterinary Laboratories Agency, Waybridge, UK
H5N1 A/turkey/Poland/35
/07(Po)




Clade 1 Dr. T. van den Berg (CODA-CERVA, Brussels, Belgium)
Table 2
Design of immunization and challenge experiments.
Experiment/route Group size Respective treatment day after hatching
Imm Cntr Cnct Prime/boost Blood Challenge
Immunization (broilers) Trial 1/sc 14 10 n/a 10/22 21/42 n/a
Trial 2/sc 28 14 n/a 5/19 18/40 n/a
Trial 3/sc, im 30 10 n/a 6/21 20/42 n/a
Trial 4/im 24 5 n/a 7/21 20/38 n/a
Trial 5/im 24 3 n/a 7/21 20/42 n/a
Challenge (SPF) Exp 1/im 10 3 2 7/21 21/35/42/56 42
Exp 2/im 5 2 1 7/21 21/35/42/63/ 70/77 77
Exp 3/im 10 5 2 7/21 21/35/42/56 42
Routes of immunization (sc – subcutaneous; im – intramuscular). Imm – immunized; Cntr – control (non-immunized); Cnct – contact; prime – ﬁrst immunization; boost –
second immunization; blood – blood collection; challenge – experimental infection with H5N1 virus; n/a – non-applicable. For all experiments with experimental infection
(challenge) SPF (speciﬁc pathogen free) chickens were used.
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(Oxford Expression Technologies, UK). Bound IgY were detected
using goat anti-chicken IgY (Fc-speciﬁc)-HRP (Pierce/Thermo
Scientiﬁc, IL, USA) antibodies. Results were analyzed using the
STATISTICA program (StatSoft, Poland).Hemagglutinin Inhibition
The HI test was conducted according to the standard procedure
[1]. Shortly, the collected sera (25 ll of sera in serial twofold dilu-
tions) were incubated for 25 min in a titration plate with four HA
units of the inactivated antigen. Next, a suspension of 1% hen
erythrocytes was added and incubated for 30 min. The HI titer
was determined as the reciprocal of the highest dilution in which
hemagglutination was inhibited. Sera from Trials 1 to 5 were tested
using the heterologous strain H5N2 A/chicken/Belgium/150/1999
(GD Deventer, Netherlands). Sera from the Challenge Experiments
1–3 were tested with a much broader range of antigens (see
Table 1).Determination of viral titers
The level of viral RNA in samples from challenged chickens was
assayedby quantitative real timeRT-PCR/MusingRNA isolatedwith
the RNeasy Mini Kit (Qiagen, Hilden, Germany) as described [21].
Oligonucleotides M-25 (50-AGATGAGTCTTCTAA CCGAGGTCG-30)
and M-124 (50-TGCAAAAACATC TTCAAGTCTCT-30) were used as
primers and M-64 (50-FAM-TCAGGCCCCCTC AAAGCCGA-TAMRA-
30) served as a probe. Quantitative standards of RNA extracted from
10-fold dilutions of a titrated virus homologous to the challengestrain were used to convert and express the QRT-PCR Ct values as
equivalent EID50 (eqEID50) permilliliter of swab ﬂuid from orophar-
yngea and cloaca.Results
Immune responses of chickens to DNA vaccines
Five independent immunization experiments with slightly dif-
ferent time schedule of priming, boosting and blood collection
were conducted in experimental farm conditions (Table 2, Fig. 1).
The duration of each experiment did not exceed 6 weeks, the life
span of broilers. In the initial experiment (Trial 1) we focused on
the evaluation of the immunogenic potential of two variants (short
and long) of the DNA vaccine. The plasmid containing the long se-
quence appeared to be better vaccine candidate than the one with
the short (H1) sequence (Fig. 1A), therefore we concentrated only
on the long DNA vaccine in further experiments. The minimal
amount of plasmid DNA inducing satisfactory response by subcuta-
neous route was assessed in the next experiment (Trial 2) as
125 lg (Fig. 1B). When two high doses of 250 lg DNA were admin-
istered without Lipofectin the anti-HA response was signiﬁcantly
lower than the response to two doses of 250 lg or two doses of
125 lg administered with the carrier.
Subsequent trials (Trials 3–5) (i) allowed us to choose the
intramuscular route as superior to the subcutaneous, (ii) conﬁrmed
that the intramuscularly injected dose of 125 lg of the long variant
of the DNA vaccine is sufﬁcient to induce anti-HA humoral
response in 100% of chicken, and (iii) demonstrated that two doses
of the vaccine are necessary to induce antibodies capable of
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sistently indicated that two weeks after priming (just before boost-
ing) anti-HA antibodies could be detected in sera. However, the
second dose of the vaccine (boosting) resulted in a strong increase
of anti-HA antibody titers in most groups (as detected 3 weeks
after the boost) and in increase of hemagglutinin inhibition (HI)
activity (Fig. 1 and Supplementary Fig. 1). Generally, irrespective
of the experimental group, no HI activity was detected in sera with
low titers of anti-HA antibodies.Fig. 1. Chicken immune responses to DNA vaccine. Anti-HA Ab measured by ELISA (A–C
The number (n) of chicken per group is indicated; sc, subcutaneous; im, intramuscular;
vector; (-)carrier – chickens received DNA without lipid carrier; doses of DNA (250, 125 o
where 1 denotes the group which received only the ﬁrst dose. In Trial 1 (A) either the s
only the long variant was used.Dynamics of serological response
Thepreviously optimized immunization schedule (intramuscular
route, 125-lg dose, prime/boost on days 7/21) was applied to SPF
chickens. Then, on day 42 (Experiment 1 and 3) or 77 (Experiment
2) chickens were challenged with either H5N1 HPAIV from clade
2.2 (Experiments 1–2) or H5N1 HPAIV from clade 1 (Experiment 3).
The HI response in sera of immunized and challenged chickens is
shown in Fig. 2 and Supplementary Fig. 2. Consistently, the best HI) and HI of corresponding sera (C) are shown for individual chickens in each group.
buffer – chickens received two doses of buffer; vector – chickens received empty
r 62 lg) are speciﬁed; chickens were immunized twice unless indicated otherwise,
hort or long variant of the vaccine was used, while in Trials 2 (B) and Trials 3–5 (C)
Fig. 2. Dynamics of HI titer in immunized and infected groups of chickens. Chickens
in Experiments 1 and 2 were challenged with H5N1 from clade 2.2 (homologous to
the vaccine), while in Experiment 3 with H5N1 from heterologous clade 1.
Challenge was on day 42 in Experiments 1 and 3 and on day 77 in Experiment 2.
Chickens from the control (non-immunized) groups had no detectable serological
response to any of the antigens tested and they are not shown. Annotations on
horizontal axes refer to the type of virus used for HI test (Sc – A/Ck/Scot/59; Po – A/
turkey/Poland/35/07; Be – A/crested eagle/Belgium/01/2004) and to the day of
blood collection.
Fig. 3. Results of challenge experiments. (A) Experiment 1 – infection with
homologous HPAIV three weeks post boost (wpb). (B) Experiment 2 – infection
with homologous HPAIV 8 wpb. (C) Experiment 3 – infection with heterologous
HPAIV 3 wpb. The data are shown as percentage survival in respective groups (c –
control chickens, cc – contact chickens, ic – immunized chickens).
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the DNA vaccine. At 3 weeks post booster (wpb) (challenge day in
Experiment 1 and Experiment 3) all birds were HI-positive with
the following values of Geometric Mean Titers (GMT): 169 (Experi-
ment 1), 97 (Experiment 2) and 111 (Experiment 3). However, only
60–80% of birds tested on the challenge day (3 wpb or 8 wpb) were
found positive with antigen from heterologous and antigenically
distant clade and the percentage of seropositive chickens never
reached 100%. The strong elevation of HI antibody was always ob-
served 2 weeks after challenge.
Protection against challenge and viral shedding
The survival ratio after the challenge is shown in Fig. 3, while the
amount of viral RNA in swabs collected from the immunized/
infected and the contact groups is summarized in Table 3. All control
chickens (non-immunized, challenged) died by 3 dpi and large
amounts of the virus (usually >5log10 EID50 per ml swab ﬂuid) were
found. In Experiment 1 (challenge with the homologous virus
3 weeks after the boosting), no clinical signs or mortality were ob-
served in immunized chickens or contact birds (Fig. 3A). The small
amount of the virus (up to 3log10 EID50) was detected in oropharyn-
geal swabs of single birds tested at 3 dpi and 14 dpi. This seems,
however, to be probably below the infecting dose, which is reﬂected
in the survival of the contact birds. In Experiment 2 (challenge with
the homologous virus 8 weeks after boosting), the vaccinated and
challenged chickens remained clinically healthy, but the contact
bird developed clinical symptoms and died 7 days after the vacci-
nated birds had been challenged (Fig. 3B). The virus was found at
3 dpi in the oropharyngeal swabs collected from 2 immunized birds
(amount of RNA equivalent to 3.3log10 EID50) while in dead contact
chicken a the viral RNA was present both in respiratory and diges-
tive tracts (quantity corresponding to 6.2 and 4.6log10 EID50, respec-
tively). Regarding Experiment 3 (challenge with the virus from the
heterologous clade 3 weeks after boosting), three immunized and
infected birds died on days 5, 10 and 13, but viral RNAwas never de-
tected in swabs taken from the immunized chicken found dead at
13 dpi. Both contact chickens were found dead 2 days after they
had been placed in the isolator with the challenged birds (Fig. 3C).
The vaccinated and challenged chickens shed the virus up to
10 dpi with the peak at 3 dpi (seven birds, amount of RNA equiva-
lent to 2.4–5.8log10 EID50, see Table 3).Discussion
This work focused on testing the DNA vaccine effective in chick-
ens that can be used in case of inﬂuenza outbreak. Comparison of
two immunization routes resulted in choosing the intramuscular
injection as better and more reliable than the subcutaneous one
(Fig. 1C). This route of injection was also more convenient for the
personnel and, in our evaluation, better tolerated by birds. In other
reports this route was also often used for DNA immunizations with
HA-encoding plasmids [7,8,12,16] and gave good results; however,
other, more sophisticated methods like gene gun [9], electropora-
tion [19] or needle free jet injector [17] were sometimes found
more effective. We have also established the minimal dose induc-
ing the satisfactory response as 125 lg. In other works a very broad
range of doses was tested and showed to be effective. Usually
around 10–200 lg ensured high or average level of response and
protection [7,8,9,12,16,17,19].
The reported here immunization protocol, initially optimized in
broilers in experimental farm conditions, was used in three chal-
lenge experiments with H5N1 HPAIVs using SPF White Leghorn
chickens kept in a biosafety level 3 laboratory. Two HPAIV strains
were used for challenge. The ﬁrst was A/turkey/Poland/35/07 from
Table 3
Viral RNA detection after challenging of vaccinated chickens.
Days post infection (d.p.i.)

















Exp 1 Immun 1/10
(3log10 EID50)
0/10 0/10 0/10 0/10 0/10 1/10
(<2log10 EID50)
0/10
Contact 0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2
Exp 2 Immun 2/5
(<2–3.3 log10 EID50)
0/5 0/5 0/5 0/5 0/5 0/5 0/5




–a – – –













–d – – – – –
Results are shown for immunized (Immun) and contact chickens. Results for corresponding control groups (non-immunized and infected) are not shown. These chickens
always died by 3 dpi and had large amounts of the virus (usually >5log10 EID50 per ml of swab). The number of virus-positive (+) and of all individuals (total, t) in each group is
provided. The amount of viral RNA in shedding chickens is shown in brackets. O – oropharyngeal swabs, C – cloacal swabs.
Experimental infection (challenge) was performed on 42nd (Exp 1 and Exp 3) and on 77th day after hatching (Exp 2) with either virus from the homologous clade (Exp 1 and
Exp 2) or virus from a heterologous clade (Exp 3). Results obtained with the H5N1 virus from the clade homologous to the one used for preparing the DNA vaccine are
highlighted.
a Bird died on 7 dpi.
b Bird died on 5 dpi.
c One bird died on 10 dpi and one bird died on 13 dpi.
d Birds died on 3 and 4 dpi.
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culated for several months in European countries causing small lo-
cal outbreaks. The second was A/crested eagle/Belgium/01/04 from
the distinct clade 1 which was circulating in southern Asia for sev-
eral years and was once found at the Brussels airport in smuggled
birds [26]. The mortality rate of the challenged animals was mon-
itored, virus shedding and transmission were tested, and the
dynamics of serological response (HI test) followed. All immunized
birds were protected against the homologous virus used in chal-
lenge Experiments 1 and 2. Transmission of the virus was absent
in the challenge Experiment 1 (infection at 3 wpb), while it was ob-
served in Experiment 2 (infection at 8 wpb). As a result, a control
contact chicken died 7 days after inoculation. It should be pointed
out that shedding of the virus was mild and infection in the contact
chicken developed with a delay of several days. Of the ten chickens
vaccinated in Experiment 3 (challenge with heterologous H5N1
HPAIV) two died and had moderate to high levels of viral RNA in
oropharyngeal and cloacal swabs, as well as in the lung, brain, kid-
ney and spleen samples. The third chicken died also at the last day
of observation. However, it was clinically healthy throughout the
experiment and no virus RNA was detected at any time; therefore,
we assumed that the reason of its death could be other than viral
infection. The two contact chickens also died, proving transmission
of the virus from vaccinated chickens. However, in order to get sta-
tistically signiﬁcant results concerning virus transmission from the
vaccinated to not-vaccinated birds it would be necessary to use a
larger group of contact birds.
The H5N1 virus is highly variable and the existence of multiple
antigenic and genetic variants makes the generation of a universal
vaccine difﬁcult or even impossible. A partial solution to the prob-
lem may be a ‘‘multi-clade’’ DNA vaccine which should potentially
protect against a broader spectrum of viruses [28]. Vaccination
against avian inﬂuenza is one of the tools in the control of the dis-
ease and generation of a vaccine that elicits even partial protection
can greatly help limit the spread of infections in susceptible popu-
lations. The reported DNA vaccine provides 100% and 70% protec-
tion against, respectively, a homologous and heterologous virus
and fulﬁlls the criteria established by the World Organization forAnimal Health for an efﬁcient AI vaccine [24]. The major advantage
of this vaccine is that it can be used as a part of a DIVA strategy
since the antibodies are produced exclusively against viral hemag-
glutinin. Although it still needs to be optimized in order to reduce
its cost, optimize the immunization schedule and/or administra-
tion route, we believe that the similar DNA vaccines can be used
in future as part of prophylactic, preventive or emergency strate-
gies in the protection of valuable ﬂocks against H5N1.
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